Table 1.
In vitro activity of imipenem/relebactam against selected clinical isolates
| Pathogen | No. of isolates | % susceptible (MIC90 [µg/mL]) | ||||||
|---|---|---|---|---|---|---|---|---|
| IMI/REL | IMI | PIP/TZP | FEP | AMK | CEF | COL | ||
| All Enterobacterales [22–26] | 71,345 | 93.1–99.1 (1) | 86.7–97.4 (8) | 79.3–90.6 (> 64) | 50.4–89.7 (> 32) | 74.4–99.6 (16) | 60–86.7 (> 32) | 84.3–95.7 (2) |
| CEF-NS [22, 24] | 4993 | 94.1–98.7 (0.5) | 90.2–90.5 (1) | 39.8–48.7 (> 64) | 19.1–34.1 (> 32) | 87.8–98.0 (8) | 0 (> 32) | 92.5–93.4 (≤ 1) |
| FEP-NS [22, 24] | 4334 | 93.4–98.4 (0.25) | 89.2–89.8 (2) | 40.2–60.6 (> 64) | 0 (> 32) | 86.0–97.3 (16) | 7.6–17.6 (> 32) | 94.0–96.1 (≤ 1) |
| IMI-NSa [24, 25] | 1639 | 42.4–66.3 (> 32) | 0 (> 32) | 6.3–20.9 (> 64) | 9.3–15.4 (> 32) | 50.9–54 (>32) | 6.5–16 (> 32) | 67.1–83.6 (> 4) |
| PIP/TZP-NS [22, 24] | 3944 | 92.5–98.1 (0.5) | 86.8–87.8 (4) | 0 (> 64) | 34.5–55.2 (> 32) | 85.2–97.5 (8) | 24.6–27.0 (> 32) | 91.3–91.9 (≤ 1) |
| MDR [22–24] | 6519 | 92.1–98.2 (0.5) | 82.3–89.8 (2) | 36.7–50.6 (> 64) | 13–39.0 (> 32) | 86.7–97.8 (8) | 4.8–23.6 (> 32) | 84.8–92.2 (≤ 1) |
| KPC-positive [24, 26] | 563 | 94.6–98.6 (1) | 1.4–3.1 (> 32) | 0–0.5 (> 64) | 1.4–4.0 (> 32) | 34.8–70.6 (> 32) | 0.7–5.2 (> 32) | 73.2–73.9 (> 4) |
| Pseudomonas aeruginosa [23, 27] | 14,902 | 90.8–93.9 (2) | 69.0–72.0 (16) | 69.1–70.2 (> 64) | 75.0–75.6 (32) | 91.1–96.0 (16) | 74.3–76.9 (> 32) | 99.0–99.6 (≤ 1) |
| CEF-NS [27] | 3132 | 69.6 (> 32) | 34.4 (> 32) | 8.6 (> 64) | 17.7 (> 32) | 72.6 (> 32) | 0 (> 32) | 98.2 (2) |
| FEP-NS [27] | 3047 | 67.2 (> 32) | 30.4 (> 32) | 10.3 (> 64) | 0 (> 32) | 69.9 (> 32) | 15.4 (> 32) | 98.2 (2) |
| IMI-NS [27] | 3776 | 70.3 (> 32) | 0 (> 32) | 36.8 (> 64) | 43.9 (> 32) | 76.0 (> 32) | 45.6 (> 32) | 98.4 (2) |
| PIP/TZP-NS [27] | 3760 | 73.1 (> 32) | 36.5 (> 32) | 0 (> 64) | 27.3 (> 32) | 76.9 (> 32) | 23.8 (> 32) | 98.6 (≤ 1) |
| MDR [23, 27] | 4594 | 70.7–82.2 (> 32) | 28.8–38.9 (> 32) | 10.0–15.8 (> 64) | 21.1–29.6 (> 32) | 72.9–89.8 (> 32) | 20.3–32.4 (> 32) | 97.9–99.0 (2) |
Pathogens against which imipenem/cilastatin/relebactam has demonstrated efficacy in SMART surveillance program [22–27]. Clinical isolates were collected in the EU (2015–2017 [24]), USA (2015–2017 [23], 2016 [22]), China (2015–2018 [25]) or worldwide (2015–2016 [27], 2017 [26]). Not all studies reported MIC90. Some data are available only as abstracts/posters [26]
AMK amikacin, CEF ceftazidime, COL colistin, FEP cefepime, KPC Klebsiella pneumoniae carbapenemase, IMI imipenem, IMI/REL imipenem/relebactam, MIC90 minimum inhibitory concentration required to inhibit 90% of isolates, MDR multidrug resistant, NS nonsusceptible, PIP/TZP piperacillin/ tazobactam
aIncluding isolates carrying metallo-β-lactamases and/or OXA-48-like carbapenemases